Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Rapport targets neurological and psychiatric disorders, aligning with neuropsychiatric drug development.
|
$978.51M |
$26.81
-0.19%
|
|
IART
Integra LifeSciences Holdings Corporation
Direct neurosurgery devices and surgical implants (e.g., CerebroFlo EVD catheter, Aurora Surgiscope) are core products.
|
$966.87M |
$12.40
-1.98%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
PLSE
Pulse Biosciences, Inc.
Pulse Biosciences develops nsPFA-based medical devices (e.g., CellFX platform) for non-thermal tissue ablation across soft tissue and cardiac indications.
|
$958.72M |
$14.25
+1.06%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$948.91M |
$4.58
-7.58%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$913.93M |
$16.77
+0.48%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$912.22M |
$12.79
-3.22%
|
|
CLB
Core Laboratories N.V.
CLB provides laboratory testing and advisory services via proprietary tracers and reservoir analysis capabilities.
|
$911.15M |
$19.46
-0.82%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$895.69M |
$12.21
+0.62%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$888.88M |
$5.39
+26.94%
|
|
INMD
InMode Ltd.
InMode's core business is medical devices and biometrics, with RF-based aesthetic platforms and related systems.
|
$881.73M |
$13.95
-0.71%
|
|
PSNL
Personalis, Inc.
NeXT Personal is a tumor-informed liquid biopsy-based MRD test, central to PSNL's offerings.
|
$877.02M |
$9.89
+2.91%
|
|
URGN
UroGen Pharma Ltd.
ZUSDURI (UGN-102) is an oncology therapeutic developed by UroGen, placing the company in Biotech - Oncology.
|
$869.77M |
$18.85
-3.53%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$860.91M |
$19.14
-7.31%
|
|
FLGT
Fulgent Genetics, Inc.
Company operates clinical lab chains providing diagnostic testing.
|
$859.50M |
$28.10
-1.92%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$853.98M |
$2.35
+5.86%
|
|
NUTX
Nutex Health, Inc.
Nutex Health operates micro-hospitals and provides hospital services including acute inpatient care and emergency/observation services.
|
$850.27M |
$153.45
-6.55%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$848.94M |
$20.18
+1.25%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$846.27M |
$20.83
-4.89%
|
|
MATW
Matthews International Corporation
Memorialization segment includes embalming chemicals and funeral supplies (memorialization products).
|
$842.44M |
$27.35
-4.67%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$841.83M |
$6.07
-2.10%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$835.80M |
$1.30
|
|
JANX
Janux Therapeutics, Inc.
Company focuses on tumor-activated oncology therapies (TRACTr/TRACIr), placing JANX squarely in Biotech - Oncology.
|
$826.89M |
$13.76
+0.26%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$817.67M |
$10.03
-0.10%
|
|
CBLL
CeriBell, Inc.
Ceribell's core product is a point-of-care diagnostic EEG system (diagnostic equipment).
|
$804.41M |
$21.97
-3.81%
|
Showing page 15 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
